The large public attention associated with the influenza A (H1N1, swine flu)
pandemic in 2009 increased awareness of the importance of seasonal influenza
vaccination. Datamonitor predicts that the seasonal influenza vaccine market
will grow to $4.7bn by 2021/22, and will be driven by changes in national
recommendations to include additional target populations, particularly
Features and benefits
Quantifies the predicted number of people eligible for seasonal influenza
vaccination across the seven major markets.
Provides detailed sales forecasts for each of the seven major markets
based on the expected coverage rates for different population groups.
Explains the major growth drivers in the seasonal influenza vaccine
market, including predicted changes to national recommendations.
Identifies which markets provide the greatest opportunity for growth.
Over the forecast period, the seasonal influenza vaccine market in the seven
major markets is set to increase from combined sales of $3.6bn in 2011/12 to
$4.7bn in 2021/22. Growth is driven by a broadening of recommendations across
the seven major markets and by increased awareness of the benefits of
The US is the largest single market for influenza vaccines, and growth has
been driven by price increases, increased coverage rates after the 2009
influenza pandemic, and the introduction of a universal recommendation in
2010. Campaigning by US authorities will continue to increase coverage rates;
however, growth is expected to slow.
Datamonitor predicts that each of the five major EU markets will include
children aged <5 years and school-aged children of 5 - 17 years in their
national recommendations, substantially increasing the number of people
eligible for vaccination during the forecast period.
Your key questions answered
How was the seasonal influenza vaccine market affected by the 2009
influenza A (H1N1, swine flu) pandemic?
Which countries are predicted to broaden recommendations for influenza
vaccination over the next 10 years?
How many people are eligible for influenza vaccination in each of the
seven major markets?
How will sales in seasonal influenza vaccines evolve for each market
during the forecast period?
Which of the seven major markets provides the greatest opportunity for
Table of Contents
Table of Contents
Strategic scoping and focus
Datamonitor key findings
Market definition for this disease
Forecast methodology and assumptions
MARKET OVERVIEW AND CONTEXT
Current and future market dynamics overview
Vaccination recommendations in the seven major markets
Vaccination coverage rates in the seven major markets
Seven major markets influenza vaccine forecast, 2012/13 - 2021/22
Market Forecasts: Seasonal Influenza Vaccines - Broadened recommendations and increased awareness boost sales in the seasonal influenza vaccine market published by Datamonitor in August 29, 2012. This report consists of Pages: 86 and the price starts from US $ 11400.